Tennessee Oncology contributes to global clinical trial for KRAS G12C lung cancer therapy
Researchers at Tennessee Oncology participated in a global study demonstrating improved survival outcomes for patients treated with a new KRAS G12C inhibitor.
Clinical researchers at Tennessee Oncology's Greco-Hainsworth Centers for Research served as key investigators in a global trial evaluating a new generation of therapy for KRAS G12C-mutated lung cancer. The study indicates that the administration of this targeted therapy leads to increased overall survival rates in patients compared to existing standard treatments.
Targeted therapies for KRAS G12C mutations address a historically difficult-to-treat subset of non-small cell lung cancer. By inhibiting the specific protein responsible for tumor growth in these patients, the trial aimed to provide a more effective intervention than traditional chemotherapy.
The findings contribute to a growing body of evidence regarding the efficacy of molecularly targeted treatments in oncology. Tennessee Oncology continues to expand its participation in multicenter clinical trials to broaden patient access to emerging therapeutic options within the Nashville region and beyond.